Clovis Oncology, Inc. (CLVS) Is At $58.72 Formed Wedge; Intercept Pharmaceuticals, Inc. (ICPT) Covered By 12 Bulls

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 73 analyst reports since August 10, 2015 according to SRatingsIntel. Cowen & Co maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Monday, June 12. Cowen & Co has “Buy” rating and $22500 target. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Market Perform” rating by Wells Fargo on Friday, December 4. Morgan Stanley downgraded the shares of ICPT in report on Friday, April 8 to “Underperform” rating. Oppenheimer maintained it with “Buy” rating and $20000 target in Monday, July 31 report. Oppenheimer downgraded the shares of ICPT in report on Friday, September 22 to “Perform” rating. The firm has “Hold” rating by Wells Fargo given on Tuesday, February 13. The rating was maintained by Wedbush on Tuesday, June 13 with “Buy”. Vetr upgraded the stock to “Strong-Buy” rating in Tuesday, September 22 report. The firm has “Outperform” rating by Wedbush given on Monday, August 10. The rating was maintained by Needham with “Hold” on Monday, July 31. See Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) latest ratings:

15/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $152 New Target: $155 Maintain
13/02/2018 Broker: Wells Fargo Rating: Hold New Target: $57.0 Maintain
12/02/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain
07/02/2018 Broker: Goldman Sachs Rating: Sell New Target: $45.0 Downgrade
01/02/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain
01/02/2018 Broker: Deutsche Bank Rating: Buy New Target: $106.0
25/01/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain
22/01/2018 Broker: Credit Suisse Rating: Buy New Target: $167.0 Maintain
13/12/2017 Broker: Deutsche Bank Rating: Buy New Target: $106 Initiates Coverage On
16/11/2017 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain

Clovis Oncology, Inc. (CLVS) formed wedge down with $53.44 target or 9.00% below today’s $58.72 share price. Clovis Oncology, Inc. (CLVS) has $2.97 billion valuation. The stock decreased 0.53% or $0.31 during the last trading session, reaching $58.72. About 745,048 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since March 19, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 61 analyst reports since September 10, 2015 according to SRatingsIntel. On Wednesday, August 24 the stock rating was maintained by Mizuho with “Neutral”. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Outperform” rating by RBC Capital Markets on Thursday, February 22. The company was upgraded on Thursday, January 26 by Piper Jaffray. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Friday, January 27 by Bank of America. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, September 11. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Hold” rating by WallachBeth Capital on Tuesday, November 17. The firm has “Neutral” rating given on Monday, November 16 by Mizuho. The firm has “Neutral” rating given on Monday, June 19 by Chardan Capital Markets. SunTrust maintained it with “Buy” rating and $30 target in Wednesday, August 24 report. The stock has “Neutral” rating by Mizuho on Monday, January 25.

Since October 16, 2017, it had 0 insider purchases, and 7 sales for $1.62 million activity. The insider IVERS-READ GILLIAN C sold 3,000 shares worth $162,270. On Thursday, March 8 the insider SPICKSCHEN THORLEF sold $276,615.

Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.39, from 1.44 in 2017Q2. It fall, as 48 investors sold Clovis Oncology, Inc. shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Rmb Cap Mgmt Limited Liability Corp holds 0.04% or 19,140 shares in its portfolio. Cornerstone Management has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). The New Mexico-based Hanseatic Management Svcs has invested 0.27% in Clovis Oncology, Inc. (NASDAQ:CLVS). Fisher Asset Lc accumulated 26,633 shares. Manufacturers Life Insurance The holds 33,260 shares. Tekla Cap Mngmt Llc holds 0.22% or 75,400 shares in its portfolio. 2,567 were accumulated by Lpl Lc. Public Employees Retirement Association Of Colorado stated it has 7,578 shares. Metropolitan Life invested in 29,294 shares or 0.02% of the stock. The New Jersey-based Lord Abbett & Lc has invested 0.07% in Clovis Oncology, Inc. (NASDAQ:CLVS). Ray Gerald L & Associates Ltd owns 0.44% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 42,630 shares. Rhumbline Advisers reported 53,709 shares. 24,283 are owned by State Board Of Administration Of Florida Retirement System. California-based Rice Hall James Limited Liability Corporation has invested 0.44% in Clovis Oncology, Inc. (NASDAQ:CLVS). State Of Wisconsin Invest Board holds 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 43,082 shares.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on May, 2. They expect $-1.34 earnings per share, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.27 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 5.51% negative EPS growth.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $1.64 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: